SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2023 after market close on Monday, May 8, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
On Wednesday, May 10, 2023, at 11:20 a.m. Pacific Time, Shockwave Medical management is scheduled for a fireside chat at the BofA Securities 2023 Healthcare Conference, which is taking place from Tuesday, May 9 – Thursday, May 11, 2023 at the Encore Hotel in Las Vegas, NV.
Interested parties may access live and archived webcasts of these events on the “Investors” section of the company’s website at https://ir.shockwavemedical.com. Investors interested in dialing in to the first quarter 2023 Shockwave Medical earnings conference call on Monday May 8, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time may do so by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID:13737254.
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
investors@shockwavemedical.com
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…